83508 Federal Register / Vol. 89, No. 200 / Wednesday, October 16, 2024 / Notices 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Division of Intramural 

Research Board of Scientific Counselors, 

NIAID. 

Date: December 9–11, 2024. 

Time: 8:00 a.m. to 10:15 a.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Address: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, Building 50, Conference Room 1227/ 

1233, 50 Center Drive, Bethesda, MD 20892. 

Contact Person: Laurie Lewallen, 

Committee Manager, Division of Intramural 

Research, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, Building 33, Room 1N24, 33 North 

Drive, Bethesda, MD 20892, 301–761–6362, 

Laurie.Lewallen@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 10, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23836 Filed 10–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Microglial Pathophysiology in Comorbid 

Substance Use Disorder (SUD) and HIV. 

Date: November 5, 2024. 

Time: 2:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Meysam Yazdankhah, 

Ph.D., Scientific Review Officer, Scientific 

Review Branch, Office of Extramural Policy, 

National Institute on Drug Abuse, NIH, 301 

North Stonestreet Avenue, MSC 6021, 

Bethesda, MD 20892, (301) 402–6965, 

meysam.yazdankhah@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Mechanistic Studies on Social Behavior in 

Substance Use Disorder. 

Date: November 19, 2024. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Caitlin Elizabeth Angela 

Moyer, Ph.D., Scientific Review Officer, 

Scientific Review Branch, Office of 

Extramural Policy, National Institute on Drug 

Abuse, NIH, 301 North Stonestreet Avenue, 

MSC 6021, Bethesda, MD 20892, (301) 443– 

4577, caitlin.moyer@nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; High 

Priority HIV and Substance Use Research. 

Date: November 20, 2024. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institute of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Trinh T. Tran, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, Office of Extramural Policy, National 

Institute on Drug Abuse, NIH, 301 North 

Stonestreet Avenue, MSC 6021, Bethesda, 

MD 20892, (301) 827–5843, trinh.tran@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: October 10, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23837 Filed 10–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

[Docket No. CISA–2024–0028] 

Request for Comment on Product 

Security Bad Practices Guidance 

AGENCY: Cybersecurity and 

Infrastructure Security Agency (CISA), 

Department of Homeland Security 

(DHS). 

ACTION: Notice of availability; request 

for comment. 

SUMMARY: The Cybersecurity Division 

(CSD) within the Cybersecurity and 

Infrastructure Security Agency (CISA) 

requests feedback on draft Product 

Security Bad Practices guidance. 

Additionally, CISA requests input on 

analysis or approaches currently absent 

from the guidance. 

DATES: Written comments are requested 

on or before December 2, 2024. 

Submissions received after the deadline 

for receiving comments may not be 

considered. 

ADDRESSES: You may submit comments, 

identified by docket number CISA– 

2024–0028, by following the 

instructions below for submitting 

comments via the Federal eRulemaking 

Portal at http://www.regulations.gov. 

Instructions: All comments received 

must include the agency name and 

docket number Docket Number CISA– 

2024–0028. All comments received will 

be posted without change to http://

www.regulations.gov, including any 

personal information provided. CISA 

reserves the right to publicly republish 

relevant and unedited comments in 

their entirety that are submitted to the 

docket. Do not include personal 

information such as account numbers, 

social security numbers, or the names of 

other individuals. Do not submit 

confidential business information or 

otherwise sensitive or protected 

information. 

Docket: For access to the docket to 

read the draft Product Security Bad 

Practices Guidance or comments 

received, go to http://

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: Kirk 

Lawrence; 202–617–0036; 

SecureByDesign@cisa.dhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Public Participation 

Interested persons are invited to 

comment on this notice by submitting 

written data, views, or arguments using 

the method identified in the 

aforementioned ADDRESSES section. All 

members of the public including, but 

not limited to, specialists in the field, 

academic experts, members of industry, 

public interest groups, and those with 

relevant economic expertise are invited 

to comment. 

II. Background 

In line with CISA’s Secure by Design 

initiative, software manufacturers 

should ensure security is a core 

consideration from the onset of software 

development. CISA’s draft, voluntary 


lotter on DSK11XQN23PROD with NOTICES1